AgomAb Therapeutics NV
$10.79
▼
-9%
2026-04-21 05:09:00
agomab.com
NMS: AGMB
Explore AgomAb Therapeutics NV stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$0.28 M
Current Price
$10.79
52W High / Low
$17.45 / $9
Stock P/E
—
Book Value
$-7,123.4
Dividend Yield
—
ROCE
-24.35%
ROE
-27.25%
Face Value
—
EPS
$-1.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
57
Beta
—
Debt / Equity
0.82
Current Ratio
13.99
Quick Ratio
19.05
Forward P/E
-5.64
Price / Sales
—
Enterprise Value
$130.03 M
EV / EBITDA
-2.39
EV / Revenue
—
Rating
None
Target Price
$32
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Terns Pharmaceuticals, Inc. | $52.74 | — | $6.09 B | — | -10.92% | -14.23% | $53.19 / $2.23 | $8.96 |
| 2. | Bio-Techne Corporation | $59.22 | 116.91 | $9.33 B | 0.53% | 10.19% | 3.97% | $72.16 / $46.01 | $12.9 |
| 3. | Lexaria Bioscience Corp. | $0.99 | — | $25.53 M | — | -443.04% | -1.55% | $1.69 / $0.46 | $0.22 |
| 4. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
| 5. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 6. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 7. | IN8bio, Inc. | $1.5 | — | $14.77 M | — | -68.2% | -92.49% | $5.82 / $1.17 | $2.82 |
Quarterly Results
Figures shown in M / B
| Q4 2024 | |
|---|---|
| Sales | 0 M |
| Operating Profit | -11.81 M |
| Net Profit | -11.73 M |
| EPS in Rs | -0.24 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | — |
| Operating Profit | -48.02 M | -31.19 M | -22.63 M | — |
| Net Profit | -46.27 M | -11.39 M | -8.14 M | — |
| EPS in Rs | -0.94 | -0.23 | -0.17 | — |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 206.36 M | 171.26 M | 101 M | 84 M |
| Total Liabilities | 18.28 M | 19.82 M | 34.75 M | 41.63 M |
| Equity | 188.08 M | 151.44 M | 66.25 M | 42.36 M |
| Current Assets | 173.84 M | 139.47 M | 71.08 M | 54.43 M |
| Current Liabilities | 9.13 M | 10.88 M | 29.72 M | 33.71 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Operating CF | -46.83 M | -24.59 M | -18.97 M |
| Investing CF | -0.68 M | 40 M | -44.59 M |
| Financing CF | 96.76 M | 79.32 M | 37.63 M |
| Free CF | -47.5 M | -24.59 M | -18.97 M |
| Capex | -0.68 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -306.21% | -39.89% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.